Jaguar Health Inc (JAGX) reports an 816% revenue increase, driven by strategic out-licensing and promising clinical advancements.
Crofelemer delayed-release tablets are Jaguar's FDA-approved prescription drug under botanical guidance ("botanical drug") ...
Conte noted, "Crofelemer has been shown to have a groundbreaking reduction of parenteral support of up to 37%" in MVID patients, and emphasized the absence of other approved or in-development ...
Mytesi prescription volumes declined five point eight percent sequentially and twelve point two percent year over year in the fourth quarter, signaling ongoing weakness in core HIV-related sales. Net ...
Jaguar received an up-front payment of $16Mof non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi ® and Canalevia ®-CA1 – Jaguar’s commercialized ...
Image source: The Motley Fool. Jaguar Health (NASDAQ:JAGX) reported steady year-over-year revenue, sequential revenue growth, and positive clinical milestones for crofelemer in rare pediatric and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results